skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

Refine Results

Clear All

Specialism

Show More

Resources

Show More

Show More

Products

Show More

Show More

16 Total results for product and free and sample content found

Datamonitor Healthcare: 医療用医薬品の市場調査レポート, Biom...

2019 Q3 Outlook Webinar

15 Jul 2019

Informa Pharma Intelligence presents an essential, free session during which industry analysts present their data-driven views about what to expect during the third quarter of 2019. 

Topic immuno-oncology Infectious diseases

Scrip: 世界の医療用医薬品&製薬産業に関するニュース

Gilead Says 16 Cancer Centers Getting Ready To Administer Yescarta

By Joseph Haas 31 Oct 2017

Gilead Says 16 Cancer Centers Getting Ready To Administer Yescarta

Within weeks of its acquisition of Kite, Gilead is working to launch its first immuno-oncology drug, with a goal of training.

Topic immuno-oncology

Datamonitor Healthcare: 医療用医薬品の市場調査レポート

Immuno-Oncology Overview

By Colin White, Robert Jeng & Jolene Lau 19 Sep 2017

This is an overview of the field of immuno-oncology and the various immuno-oncology classes. Immuno-oncology is one of the most promising and fastest growing areas of cancer research, as well

Topic immuno-oncology

Datamonitor Healthcare: 医療用医薬品の市場調査レポート

PD-1/PD-L1 Inhibitors: The First Wave of Immuno-Oncology

By Dustin Phan 18 Sep 2017

PD-1/PD-L1 Inhibitors: The First Wave of Immuno-Oncology

Recently, Informa Pharma Intelligence conduced an insightful webinar regarding the current market landscape and outlook for immuno-oncology.

Topic immuno-oncology

Scrip: 世界の医療用医薬品&製薬産業に関するニュース

BMS' Opdivo Approval In CRC Overshadowed By Keytruda Dominance

03 Aug 2017

BMS' Opdivo Approval In CRC Overshadowed By Keytruda Dominance

The US FDA has approved BMS' Opdivo for previously treated patients with some forms of colorectal cancer, however direct competition from Merck's Keytruda may limit its success.

Topic immuno-oncology cancer

Scrip: 世界の医療用医薬品&製薬産業に関するニュース

PD-1 Data Emerges In Cervical Cancer

27 Jul 2017

PD-1 Data Emerges In Cervical Cancer

Leading immunotherapy agents are beginning to report early-stage data from monotherapy and combination trials in advanced cervical cancer – a treatment area with very few approved options.

Topic Cancer immuno-oncology Research Strategy

Scrip: 世界の医療用医薬品&製薬産業に関するニュース

Immuno-Oncology Outlook: Getting To The Root Of Head And Neck Cancer

25 Jul 2017

Immuno-Oncology Outlook: Getting To The Root Of Head And Neck Cancer

As PD-1 inhibitors march toward earlier-stage head and neck cancers, researchers consider ways to improve the precision of immunotherapy through better patient selection and combinations for this accessible tumor type.

Topic Cancer immuno-oncology

Scrip: 世界の医療用医薬品&製薬産業に関するニュース

Boehringer Ingelheim's Partnering Focus: An Interview With Ioannis Sapountzis

05 Jul 2017

Boehringer Ingelheim's Partnering Focus: An Interview With Ioannis Sapountzis

Trying to catch up with peers in both immuno-oncology and NASH, the German pharma has assigned Sapountzis to lead its US business development efforts.

Topic cancer immuno-oncology

Pink Sheet: 世界の薬事規制と承認審査に関するニュース

Immuno-oncology Drugs And The Trouble With Market Access

By Francesca Bruce 07 Jun 2017

Immuno-oncology Drugs And The Trouble With Market Access

The clinical potential of immuno-oncology drugs does not seem to be reflected in approaches by health technology assessment bodies, with different interpretations of data.

Topic immuno-oncology

お問い合わせ&レポートストア

専任スタッフによるデモンストレーションを兼ねたサービスの詳しいご説明、または無料トライアルを常時受け付けています。ご希望の場合は下記のフォームよりお気軽にお申し込みください。

*一部のサービスでは無料トライアルをご利用になれません。

ご質問等ございましたらお気軽にご連絡下さい。

日本(平日:9時~18時)
電話:+81 (0)3 6273 4260
Email:inquiry.jp@informa.com

オンラインショップのレポートストアでは、医療用医薬品の市場調査・分析レポートを常時1000本以上販売しています。レポート1本単位で購入でき、オンラインでご提供いたします。

お探しの情報が見つからない場合はお問い合わせ先までお気軽にご連絡ください。